Tags : Long-Term

Takeda Reports Results of Entyvio (vedolizumab) in Interim Analysis from

Shots: The ongoing P-IIIb VISIBLE OLE study involves assessing of Entyvio (SC) in adult patients with UC or CD, following enrolment and participation in the VISIBLE 1 (UC) or VISIBLE 2 (CD) studies. Patients who completed the maintenance period up to 52wks. (randomized completers) or who achieved clinical response @14wks. (non-randomized 14wks. responders) after a […]Read More

Pfizer & Eli Lilly Report Results of Tanezumab in Long-Term

Shots: The P-III A4091058 study involves assessing of Tanezumab (2.5 & 5mg, q8w) vs NSAIDS (naproxen 500 mg/celecoxib 100 mg/diclofenac extended release 75 mg, q2d) in 3,021 patients with moderate-to-severe OA in ratio 1:1:1 for 56wks. across globe + 24-week safety follow-up study The P-III A4091058 results: composite 1EPs for safety (3.8% & 7.1% vs […]Read More

Amgen to Present Long-Term Safety-Efficacy Data of Repatha (evolocumab) in

Shots: The presentation includes a collective analysis of 10 research abstracts plus results of OSLER-1 study, assessing Repatha (evolocumab) (420mg) in hypercholesterolemia patients for up to 5 yrs. & an additional RWE of FOURIER study assessing triglycerides in patients with CV risk FOURIER P-III (Further cardiovascular OUtcomes Research with PCSK9 Inhibition in Subjects with Elevated […]Read More